BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 181] [Cited by in F6Publishing: 179] [Article Influence: 25.9] [Reference Citation Analysis]
Number Citing Articles
1 Langhans B, Nischalke HD, Krämer B, Dold L, Lutz P, Mohr R, Vogt A, Toma M, Eis-Hübinger AM, Nattermann J, Strassburg CP, Gonzalez-Carmona MA, Spengler U. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:2055-66. [PMID: 31724091 DOI: 10.1007/s00262-019-02427-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
2 Piao L, Wang F, Wang Y, Yang Z, Li Q, Cui L, Yu Q. miR-424-5p Regulates Hepatoma Cell Proliferation and Apoptosis. Cancer Biother Radiopharm 2019;34:196-202. [PMID: 30676784 DOI: 10.1089/cbr.2018.2625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
3 Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int 2017;37:259-70. [PMID: 27427866 DOI: 10.1111/liv.13204] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
4 Dong X, Han Y, Zhang E, Wang Y, Zhang P, Wang C, Zhong L, Li Q. Tumor suppressor DCAF15 inhibits epithelial-mesenchymal transition by targeting ZEB1 for proteasomal degradation in hepatocellular carcinoma. Aging (Albany NY) 2021;13:10603-18. [PMID: 33833131 DOI: 10.18632/aging.202823] [Reference Citation Analysis]
5 Wang X, Qiao J, Wang R. Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20203263. [PMID: 33111935 DOI: 10.1042/BSR20203263] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lin Y, Wen Q, Guo L, Wang H, Sui G, Sun Z. A network meta-analysis on the efficacy and prognosis of different interventional therapies for early-stage hepatocellular carcinoma. Int J Hyperthermia 2018;35:450-62. [PMID: 30354777 DOI: 10.1080/02656736.2018.1507047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Thakur RS, Devaraj E. Lagerstroemia speciosa (L.) Pers. triggers oxidative stress mediated apoptosis via intrinsic mitochondrial pathway in HepG2 cells. Environ Toxicol 2020;35:1225-33. [PMID: 32697429 DOI: 10.1002/tox.22987] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Baimas-George M, Watson M, Sulzer J, Salibi P, Murphy KJ, Levi D, Martinie JB, Vrochides D, Baker EH, Ocuin L, Iannitti DA. Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation. Surg Endosc 2021;35:3122-30. [PMID: 32588344 DOI: 10.1007/s00464-020-07747-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Xi SY, Minuk GY. Role of traditional Chinese medicine in the management of patients with hepatocellular carcinoma. World J Hepatol 2018; 10(11): 799-806 [PMID: 30533181 DOI: 10.4254/wjh.v10.i11.799] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
10 Hirata M, Nagai A, Kamatani Y, Ninomiya T, Tamakoshi A, Yamagata Z, Kubo M, Muto K, Kiyohara Y, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y, Matsuda K; BioBank Japan Cooperative Hospital Group. Overview of BioBank Japan follow-up data in 32 diseases. J Epidemiol 2017;27:S22-8. [PMID: 28190660 DOI: 10.1016/j.je.2016.12.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
11 Liao CY, Lee CC, Tsai CC, Hsueh CW, Wang CC, Chen IH, Tsai MK, Liu MY, Hsieh AT, Su KJ. Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma. Biomed Res Int. 2015;2015:840542. [PMID: 26858957 DOI: 10.1155/2015/840542] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ren Q, Xiao X, Leng X, Zhang Q, Zhou X, Ren Z, Xiao H. MicroRNA-361-5p induces hepatocellular carcinoma cell apoptosis and enhances drug sensitivity by targeting MAP3K9. Exp Ther Med 2021;21:574. [PMID: 33850546 DOI: 10.3892/etm.2021.10006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xu H, He Y, Ma J, Zhao Y, Liu Y, Sun L, Su J. Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming. Int J Oncol 2020;57:733-42. [PMID: 32705170 DOI: 10.3892/ijo.2020.5098] [Reference Citation Analysis]
14 Liu C, Wu J, Chang Z. Trends and Age-Period-Cohort Effects on the Prevalence, Incidence and Mortality of Hepatocellular Carcinoma from 2008 to 2017 in Tianjin, China. Int J Environ Res Public Health 2021;18:6034. [PMID: 34199687 DOI: 10.3390/ijerph18116034] [Reference Citation Analysis]
15 Lin L, Xiang X, Su S, Liu S, Xiong Y, Ma H, Yuan G, Nie D, Tang G. Biological Evaluation of [18F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma. Front Chem 2021;9:630452. [PMID: 33937189 DOI: 10.3389/fchem.2021.630452] [Reference Citation Analysis]
16 Zhang Y, Wang J, Qu Y, Chen Y. 6-Shogaol Suppresses the Progression of Liver Cancer via the Inactivation of Wnt/[Formula: see text]-Catenin Signaling by Regulating TLR4. Am J Chin Med 2021;49:2033-48. [PMID: 34961414 DOI: 10.1142/S0192415X21500968] [Reference Citation Analysis]
17 Li J, Zhu C, Yue P, Zheng T, Li Y, Wang B, Meng X, Zhang Y. Identification of glycolysis related pathways in pancreatic adenocarcinoma and liver hepatocellular carcinoma based on TCGA and GEO datasets. Cancer Cell Int 2021;21:128. [PMID: 33607990 DOI: 10.1186/s12935-021-01809-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yang X, Song D, Zhang J, Yang X, Feng H, Guo J. PRR34-AS1 sponges miR-498 to facilitate TOMM20 and ITGA6 mediated tumor progression in HCC. Exp Mol Pathol 2021;120:104620. [PMID: 33609562 DOI: 10.1016/j.yexmp.2021.104620] [Reference Citation Analysis]
19 Nguyen J, Jiao J, Smoot K, Watt GP, Zhao C, Song X, Stevenson HL, McCormick JB, Fisher-Hoch SP, Zhang J, Futreal PA, Beretta L. Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 2018;9:29495-507. [PMID: 30034633 DOI: 10.18632/oncotarget.25685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
20 He L, Wang S, Ma X. The Influence of ICAM1 3'UTR Gene Polymorphism on the Occurrence and Metastasis of Primary Liver Cancer. Biomed Res Int 2021;2021:7377299. [PMID: 34869770 DOI: 10.1155/2021/7377299] [Reference Citation Analysis]
21 Deng G, Luo Y, Zhang Y, Zhang J, He Z. Enabled homolog (ENAH) regulated by RNA binding protein splicing factor 3b subunit 4 (SF3B4) exacerbates the proliferation, invasion and migration of hepatocellular carcinoma cells via Notch signaling pathway. Bioengineered 2022;13:2194-206. [PMID: 35030977 DOI: 10.1080/21655979.2021.2023983] [Reference Citation Analysis]
22 Wang J, Li Y, Zhang C, Chen X, Zhu L, Luo T. A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma. Transl Cancer Res 2021;10:3979-92. [PMID: 35116696 DOI: 10.21037/tcr-21-741] [Reference Citation Analysis]
23 Wang L, Wang FS. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int 2019;13:521-33. [PMID: 31352593 DOI: 10.1007/s12072-019-09967-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
24 Gubay F, Staunton R, Metzig C, Abubakar I, White PJ. Assessing uncertainty in the burden of hepatitis C virus: Comparison of estimated disease burden and treatment costs in the UK. J Viral Hepat 2018;25:514-23. [PMID: 29274178 DOI: 10.1111/jvh.12847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Cocker F, Chien Yee K, Palmer AJ, de Graaff B. Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide. Aust N Z J Public Health 2019;43:267-73. [PMID: 30958629 DOI: 10.1111/1753-6405.12889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
26 He K, Chen H, Cao T, Lin J. Elucidation of the Mechanisms and Molecular Targets of Shuanglian Decoction for the Treatment of Hepatocellular Carcinoma Based on Network Pharmacology. ACS Omega 2021;6:917-24. [PMID: 33458543 DOI: 10.1021/acsomega.0c05550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zeng T, Wang D, Chen J, Chen K, Yu G, Chen Q, Liu Y, Yan S, Zhu L, Zhou H, Huang A, Tang H. AF119895 regulates NXF3 expression to promote migration and invasion of hepatocellular carcinoma through an interaction with miR-6508-3p. Exp Cell Res 2018;363:129-39. [PMID: 29274323 DOI: 10.1016/j.yexcr.2017.12.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Liu P, Chen L, Zhang H. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. J Immunol Res 2018;2018:1206737. [PMID: 30255103 DOI: 10.1155/2018/1206737] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
29 Rapisarda V, Loreto C, Malaguarnera M, Ardiri A, Proiti M, Rigano G, Frazzetto E, Ruggeri MI, Malaguarnera G, Bertino N, Malaguarnera M, Catania VE, Di Carlo I, Toro A, Bertino E, Mangano D, Bertino G. Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol 2016; 8(13): 573-590 [PMID: 27168870 DOI: 10.4254/wjh.v8.i13.573] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
30 Andersson M, Jalnefjord O, Montelius M, Rizell M, Sternby Eilard M, Ljungberg M. Evaluation of response in patients with hepatocellular carcinoma treated with intratumoral dendritic cell vaccination using intravoxel incoherent motion (IVIM) MRI and histogram analysis. Acta Radiol 2021;:2841851211065935. [PMID: 34904868 DOI: 10.1177/02841851211065935] [Reference Citation Analysis]
31 Zhang Q, Matsuura K, Kleiner DE, Zamboni F, Alter HJ, Farci P. Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology. J Transl Med. 2016;14:328. [PMID: 27894309 DOI: 10.1186/s12967-016-1085-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
32 Ciccarelli O, Colson A, De Saeger C, Reding R, Sempoux C, Leclercq IA, Stärkel P. Tumoral response and tumoral phenotypic changes in a rat model of diethylnitrosamine-induced hepatocellular carcinoma after salirasib and sorafenib administration. Onco Targets Ther 2018;11:7143-53. [PMID: 30410370 DOI: 10.2147/OTT.S176903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sun C, Ma S, Chen Y, Kim NH, Kailas S, Wang Y, Gu W, Chen Y, Tuason JPW, Bhan C, Manem N, Huang Y, Cheng C, Zhou Z, Zhou Q, Zhu Y. Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis. Front Oncol 2022;12:843880. [DOI: 10.3389/fonc.2022.843880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Tseng P, Sie Z, Liu M, Lin H, Yang W, Lin T, Hsieh H, Hung S, Cheng C, Wang H, Chang H, Yuh C. Identification of Two Novel Small Compounds that Inhibit Liver Cancer Formation in Zebrafish and Analysis of Their Conjugation to Nanodiamonds to Further Reduce Toxicity. Adv Therap 2019;2:1900105. [DOI: 10.1002/adtp.201900105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
35 Wang Z, Mu K, Lv Y, Zhao L, Li B, Hao Y, Wang N. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients. Ir J Med Sci. [DOI: 10.1007/s11845-021-02851-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, Asad A, Preen DB, MacQuillan G, Garas G, Adams LA, Jeffrey GP. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy. Dig Dis Sci 2020;65:647-57. [PMID: 31440998 DOI: 10.1007/s10620-019-05781-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Zhu X, Zhang Y, Wu Y, Diao W, Deng G, Li Q, Wu C. HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters. Int J Genomics 2022;2022:9451557. [PMID: 35800617 DOI: 10.1155/2022/9451557] [Reference Citation Analysis]
38 Xin X, Li Q, Fang J, Zhao T. LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers. Front Oncol 2021;11:679244. [PMID: 34367966 DOI: 10.3389/fonc.2021.679244] [Reference Citation Analysis]
39 Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget. 2018;9:37721-37732. [PMID: 30701027 DOI: 10.18632/oncotarget.26507] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
40 Liu HM, Tan HY, Lin Y, Xu BN, Zhao WH, Xie YA. MicroRNA-1271-5p inhibits cell proliferation and enhances radiosensitivity by targeting CDK1 in hepatocellular carcinoma. J Biochem 2020;167:513-24. [PMID: 32275316 DOI: 10.1093/jb/mvz114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
41 Liu T, Shi Q, Yang L, Wang S, Song H, Wang Z, Xu X, Liu H, Zheng H, Shen Z. Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma. BMC Cancer 2021;21:957. [PMID: 34445994 DOI: 10.1186/s12885-021-08714-7] [Reference Citation Analysis]
42 Yu Q, Xiang L, Yin L, Liu X, Yang D, Zhou J. Loss-of-function of miR-142 by hypermethylation promotes TGF-β-mediated tumour growth and metastasis in hepatocellular carcinoma. Cell Prolif 2017;50. [PMID: 28963738 DOI: 10.1111/cpr.12384] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
43 Oversoe SK, Clement MS, Weber B, Grønbæk H, Hamilton-Dutoit SJ, Sorensen BS, Kelsen J. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer 2021;21:376. [PMID: 33827453 DOI: 10.1186/s12885-021-08103-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Dai X, Huang R, Hu S, Zhou Y, Sun X, Gui P, Yu Z, Zhou P. A novel miR-0308-3p revealed by miRNA-seq of HBV-positive hepatocellular carcinoma suppresses cell proliferation and promotes G1/S arrest by targeting double CDK6/Cyclin D1 genes. Cell Biosci 2020;10:24. [PMID: 32128112 DOI: 10.1186/s13578-020-00382-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Pu J, Qin Z, Fang Q, Huang Y, Lu Y, Li W, Wang J, Tang Q, Zeng D, Wei H. Hypoxia-induced HIF1A Activates DUSP18-mediated MAPK14 Dephosphorylation to Promote Hepatocellular Carcinoma Cell Migration and Invasion. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153955] [Reference Citation Analysis]
46 Zhao L, Hu K, Cao J, Wang P, Li J, Zeng K, He X, Tu PF, Tong T, Han L. lncRNA miat functions as a ceRNA to upregulate sirt1 by sponging miR-22-3p in HCC cellular senescence. Aging (Albany NY) 2019;11:7098-122. [PMID: 31503007 DOI: 10.18632/aging.102240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
47 Ratti F, Cipriani F, Fiorentini G, Catena M, Paganelli M, Aldrighetti L. Reappraisal of the advantages of laparoscopic liver resection for intermediate hepatocellular carcinoma within a stage migration perspective: Propensity score analysis of the differential benefit. J Hepatobiliary Pancreat Sci 2020;27:510-21. [PMID: 32189450 DOI: 10.1002/jhbp.736] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
48 Roderburg C, Berres ML, Wree A, Loosen SH, Luedde T, Trautwein C. Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visc Med 2019;35:43-6. [PMID: 31312649 DOI: 10.1159/000497465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Fernandes MT, Calado SM, Mendes-Silva L, Bragança J. CITED2 and the modulation of the hypoxic response in cancer. World J Clin Oncol 2020; 11(5): 260-274 [PMID: 32728529 DOI: 10.5306/wjco.v11.i5.260] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Tang Q, Ma C. Performance of Gd-EOB-DTPA-enhanced MRI for the diagnosis of LI-RADS 4 category hepatocellular carcinoma nodules with different diameters. Oncol Lett 2018;16:2725-31. [PMID: 30008946 DOI: 10.3892/ol.2018.8884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Lan C, Wang Y, Su X, Lu J, Ma S. LncRNA LINC00958 Activates mTORC1/P70S6K Signalling Pathway to Promote Epithelial-Mesenchymal Transition Process in the Hepatocellular Carcinoma. Cancer Invest 2021;39:539-49. [PMID: 33979257 DOI: 10.1080/07357907.2021.1929282] [Reference Citation Analysis]
52 Che N, Zhao X, Zhao N, Zhang Y, Ni C, Zhang D, Su S, Liang X, Li F, Li Y. The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma. Ann Diagn Pathol 2021;53:151755. [PMID: 34023498 DOI: 10.1016/j.anndiagpath.2021.151755] [Reference Citation Analysis]
53 Wang W, Hao LP, Song H, Chu XY, Wang R. The Potential Roles of Exosomal Non-Coding RNAs in Hepatocellular Carcinoma. Front Oncol 2022;12:790916. [PMID: 35280805 DOI: 10.3389/fonc.2022.790916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Matsuda A, Ishiguro K, Yan IK, Patel T. Therapeutic Efficacy of Vitamin D in Experimental c-MET-β-Catenin-Driven Hepatocellular Cancer. Gene Expr 2019;19:151-9. [PMID: 30157994 DOI: 10.3727/105221618X15355518848281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Matsuda A, Ishiguro K, Yan IK, Patel T. Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. Hepatol Commun 2019;3:525-41. [PMID: 30976743 DOI: 10.1002/hep4.1311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
56 Zhang Y, Li H, Chang H, Du L, Hai J, Geng X, Yan X. MTP18 overexpression contributes to tumor growth and metastasis and associates with poor survival in hepatocellular carcinoma. Cell Death Dis 2018;9:956. [PMID: 30237394 DOI: 10.1038/s41419-018-0987-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
57 Gu J, Zhang X, Miao R, Ma X, Xiang X, Fu Y, Liu C, Niu W, Qu K. A three-long non-coding RNA-expression-based risk score system can better predict both overall and recurrence-free survival in patients with small hepatocellular carcinoma. Aging (Albany NY). 2018;10:1627-1639. [PMID: 30018179 DOI: 10.18632/aging.101497] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
58 Zhang L, Zhang J, Li P, Li T, Zhou Z, Wu H. Exosomal hsa_circ_0004658 derived from RBPJ overexpressed-macrophages inhibits hepatocellular carcinoma progression via miR-499b-5p/JAM3. Cell Death Dis 2022;13:32. [PMID: 35013102 DOI: 10.1038/s41419-021-04345-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
59 Nones J, Solhaug A, Eriksen GS, Macuvele DLP, Poli A, Soares C, Trentin AG, Riella HG, Nones J. Bentonite modified with zinc enhances aflatoxin B1 adsorption and increase survival of fibroblasts (3T3) and epithelial colorectal adenocarcinoma cells (Caco-2). J Hazard Mater 2017;337:80-9. [PMID: 28511044 DOI: 10.1016/j.jhazmat.2017.04.068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
60 Lin N, Li J, Ke Q, Xin F, Zeng Y, Wang L, Liu J. Does the intermittent Pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review. PLoS One 2020;15:e0229870. [PMID: 32160231 DOI: 10.1371/journal.pone.0229870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Yang X, Xiong Q, Wu Y, Li S, Ge F. Quantitative Proteomics Reveals the Regulatory Networks of Circular RNA CDR1as in Hepatocellular Carcinoma Cells. J Proteome Res 2017;16:3891-902. [PMID: 28892615 DOI: 10.1021/acs.jproteome.7b00519] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 9.6] [Reference Citation Analysis]
62 Tian B, Zhou L, Wang J, Yang P. miR-660-5p-loaded M2 macrophages-derived exosomes augment hepatocellular carcinoma development through regulating KLF3. Int Immunopharmacol 2021;101:108157. [PMID: 34673296 DOI: 10.1016/j.intimp.2021.108157] [Reference Citation Analysis]
63 Ying D, Ruan Y, Zhou X. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway. Gene 2019;687:1-8. [PMID: 30399427 DOI: 10.1016/j.gene.2018.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
64 Zhang X, Xu L, Yang T. miR-31 Modulates Liver Cancer HepG2 Cell Apoptosis and Invasion via ROCK1/F-Actin Pathways. Onco Targets Ther 2020;13:877-88. [PMID: 32099392 DOI: 10.2147/OTT.S227467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
65 Liu Y, Guo X, Wu L, Yang M, Li Z, Gao Y, Liu S, Zhou G, Zhao J. Lipid rafts promote liver cancer cell proliferation and migration by up-regulation of TLR7 expression. Oncotarget 2016;7:63856-69. [PMID: 27588480 DOI: 10.18632/oncotarget.11697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
66 Guo L, Zheng J, Luo J, Zhang Z, Shao G. Targeting Yes1 Associated Transcriptional Regulator Inhibits Hepatocellular Carcinoma Progression and Improves Sensitivity to Sorafenib: An in vitro and in vivo Study. Onco Targets Ther 2020;13:11071-87. [PMID: 33149619 DOI: 10.2147/OTT.S249412] [Reference Citation Analysis]
67 Zhang J, Wang X, Li G, He J, Lu Z, Yang Y, Jiang Y, Jiang L, Li F, Liu J. COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC. Biomed Res Int 2021;2021:6648078. [PMID: 33824874 DOI: 10.1155/2021/6648078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Abdelmoez FA, Imam HM, Idriss NK, Wahid LA, Abbas WA, Abozaid MAA, Abdelwahab HM. The Role of Hepatitis C virus and Possible Risk factors in development of Hepatocellular carcinoma: 400 Patients based study. Egypt J Intern Med 2019;31:64-72. [DOI: 10.4103/ejim.ejim_50_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Fraum TJ, Ludwig DR, Hope TA, Fowler KJ. PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects. Gastroenterol Clin North Am 2018;47:691-714. [PMID: 30115444 DOI: 10.1016/j.gtc.2018.04.011] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
70 Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer 2019;8:281-94. [PMID: 31602371 DOI: 10.1159/000490260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
71 Serhal R, Saliba N, Hilal G, Moussa M, Hassan GS, El Atat O, Alaaeddine N. Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: In vitro inhibition of carcinogenesis. World J Gastroenterol 2019; 25(5): 567-583 [PMID: 30774272 DOI: 10.3748/wjg.v25.i5.567] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
72 Tan Y, Du B, Zhan Y, Wang K, Wang X, Chen B, Wei X, Xiao J. Antitumor effects of circ-EPHB4 in hepatocellular carcinoma via inhibition of HIF-1α. Mol Carcinog 2019;58:875-86. [PMID: 30644610 DOI: 10.1002/mc.22976] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
73 Wang B, Chu D, Cheng M, Jin Y, Luo H, Li N. Progress of HOTAIR-microRNA in hepatocellular carcinoma. Hered Cancer Clin Pract 2022;20. [DOI: 10.1186/s13053-022-00210-8] [Reference Citation Analysis]
74 Chung MW, Kim MJ, Won EJ, Lee YJ, Yun YW, Cho SB, Joo YE, Hwang JE, Bae WK, Chung IJ, Shin MG, Shin JH. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. World J Gastroenterol 2021; 27(42): 7340-7349 [PMID: 34876793 DOI: 10.3748/wjg.v27.i42.7340] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
75 Wei H, Yu X, Xue X, Liu H, Wang M, Li Y, Wang X, Ding H. Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients. Oncol Lett 2017;14:2749-56. [PMID: 28927036 DOI: 10.3892/ol.2017.6545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
76 Zhang W, Fu Q, Yao K. A three-mRNA status risk score has greater predictive ability compared with a lncRNA-based risk score for predicting prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;20:48. [PMID: 32788937 DOI: 10.3892/ol.2020.11911] [Reference Citation Analysis]
77 Bae BK, Park HC, Yoo GS, Choi MS, Oh JH, Yu JI. The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. Cancers 2022;14:2081. [DOI: 10.3390/cancers14092081] [Reference Citation Analysis]
78 Wallace MC, Preen DB, Short MW, Adams LA, Jeffrey GP. Hepatocellular carcinoma in Australia 1982-2014: Increasing incidence and improving survival. Liver Int 2019;39:522-30. [PMID: 30230194 DOI: 10.1111/liv.13966] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
79 Nandhini JT, Ezhilarasan D, Rajeshkumar S. An ecofriendly synthesized gold nanoparticles induces cytotoxicity via apoptosis in HepG2 cells. Environmental Toxicology 2021;36:24-32. [DOI: 10.1002/tox.23007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
80 Zheng J, Daniel CR, Hatia RI, Stuff J, Abdelhakeem AA, Rashid A, Chun YS, Jalal PK, Kaseb AO, Li D, Hassan MM. Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A USA-Based Study. Hepatology 2021;74:3161-73. [PMID: 34233041 DOI: 10.1002/hep.32046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Nomair AM, Madkour MA, Shamseya MM, Elsheredy HG, Shokr A. Profiling of plasma metabolomics in patients with hepatitis C-related liver cirrhosis and hepatocellular carcinoma. Clin Exp Hepatol 2019;5:317-26. [PMID: 31893244 DOI: 10.5114/ceh.2019.89478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Liu L, He C, Liu H, Wang G, Lv Z, Ni Y, Mou L, Zhan Y, Liu J. Transcriptomic profiling of long non-coding RNAs in non-virus associated hepatocellular carcinoma. Cell Biochem Biophys 2020;78:465-74. [PMID: 32405957 DOI: 10.1007/s12013-020-00915-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Zeng C, Yuan G, Hu Y, Wang D, Shi X, Zhu D, Hu A, Meng Y, Lu J. Repressing phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma by microRNA-142-3p restrains the progression of hepatocellular carcinoma. Bioengineered 2022;13:1491-506. [PMID: 34986757 DOI: 10.1080/21655979.2021.2020549] [Reference Citation Analysis]
84 Feng L, Wang Y, Wang X, An S, Aizimuaji Z, Tao C, Zhang K, Cheng S, Wu J, Xiao T, Rong W. Integrated analysis of the rhesus monkey liver transcriptome during development and human primary HCC AFP-related gene expression. Mol Ther Nucleic Acids 2021;25:406-15. [PMID: 34484865 DOI: 10.1016/j.omtn.2021.06.004] [Reference Citation Analysis]
85 Chen A, Xu C, Luo Y, Liu L, Song K, Deng G, Yang M, Cao J, Yuan L, Li X. Disruption of crosstalk between LX-2 and liver cancer stem-like cells from MHCC97H cells by DFOG via inhibiting FOXM1. Acta Biochim Biophys Sin (Shanghai) 2019;51:1267-75. [PMID: 31750892 DOI: 10.1093/abbs/gmz129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Liu C, Dai Q, Ding Q, Wei M, Kong X. Identification of key genes in hepatitis B associated hepatocellular carcinoma based on WGCNA. Infect Agent Cancer 2021;16:18. [PMID: 33726794 DOI: 10.1186/s13027-021-00357-4] [Reference Citation Analysis]
87 Wang T, Li P, Wan T, Tu B, Li J, Huang F. TIGIT/PVR and LncRNA ANRIL dual-targetable PAMAM polymeric nanoparticles efficiently inhibited the hepatoma carcinoma by combination of immunotherapy and gene therapy. J Drug Target 2021;29:783-91. [PMID: 33480288 DOI: 10.1080/1061186X.2021.1879088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
88 Jiang J, Huang Z, Chen X, Luo R, Cai H, Wang H, Zhang H, Sun T, Zhang Y. Trifluoperazine Activates FOXO1-Related Signals to Inhibit Tumor Growth in Hepatocellular Carcinoma. DNA Cell Biol 2017;36:813-21. [PMID: 28876084 DOI: 10.1089/dna.2017.3790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
89 Puranik AD, Rangarajan V, Gosavi A, Shetty N, Gala K, Kulkarni S, Mohite A, Patkar S, Goel M, Shrikhande SV, Ramaswamy A, Ostwal V, Purandare NC, Agrawal A, Shah S. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization. Nucl Med Commun 2021;42:337-44. [PMID: 33306631 DOI: 10.1097/MNM.0000000000001334] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Zhang YH, Brehmer K, Svensson A, Herlin G, Stål P, Brismar TB. Variation in textural parameters of hepatic lesions during contrast medium injection. Acta Radiol 2021;62:1317-23. [PMID: 33108894 DOI: 10.1177/0284185120964904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Holmes E, Wijeyesekera A, Taylor-Robinson SD, Nicholson JK. The promise of metabolic phenotyping in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2015;12:458-71. [PMID: 26194948 DOI: 10.1038/nrgastro.2015.114] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
92 Da B, Luo S, Huang M, Song F, Ding R, Xiao Y, Fu Y, Yang Y, Wang H, Khalaf OI. Prediction of Hepatocellular Carcinoma Prognosis and Immune Cell Infiltration Using Gene Signature Associated with Inflammatory Response. Computational and Mathematical Methods in Medicine 2022;2022:1-24. [DOI: 10.1155/2022/2415129] [Reference Citation Analysis]
93 Jun L, Yang G, Zhisu L. The utility of serum exosomal microRNAs in hepatocellular carcinoma. Biomed Pharmacother 2019;111:1221-7. [PMID: 30841435 DOI: 10.1016/j.biopha.2018.12.131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
94 Guglielmo P, Pisu N, Sanna S, Pung BLJ, Boero M. Incidental Finding on 11C-Choline-PET/CT of Hepatocellular Carcinoma Recurrence in a Prostate Cancer Patient With Negative Abdominal CT Scan. Clin Nucl Med 2020;45:703-4. [PMID: 32701803 DOI: 10.1097/RLU.0000000000003203] [Reference Citation Analysis]
95 Chen KL, Gao J. Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization. World J Gastroenterol 2021; 27(13): 1330-1340 [PMID: 33833486 DOI: 10.3748/wjg.v27.i13.1330] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
96 Jayaraman T, Lee YY, Chan WK, Mahadeva S. Epidemiological differences of common liver conditions between Asia and the West. JGH Open. 2020;4:332-339. [PMID: 32514433 DOI: 10.1002/jgh3.12275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
97 Huang L, Yang Q, Chen H, Wang Z, Liu Q, Ai S. Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway. Open Medicine 2022;17:626-37. [DOI: 10.1515/med-2022-0453] [Reference Citation Analysis]
98 Ni JY, Xu LF, Wang WD, Huang QS, Sun HL, Chen YT. Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model. J Cancer Res Clin Oncol 2017;143:199-207. [PMID: 27638772 DOI: 10.1007/s00432-016-2237-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
99 Wang CC, Tsai MC, Peng CM, Lee HL, Chen HY, Yang TW, Sung WW, Lin CC. Favorable liver cancer mortality-to-incidence ratios of countries with high health expenditure.Eur J Gastroenterol Hepatol. 2017;29:1397-1401. [PMID: 29023320 DOI: 10.1097/MEG.0000000000000969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
100 Wallace MC, Knuiman M, Huang Y, Garas G, Adams LA, MacQuillan G, Preen DB, Jeffrey GP. The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable. Dig Dis Sci 2018;63:2277-84. [PMID: 29808245 DOI: 10.1007/s10620-018-5132-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Ishiguro K, Yan IK, Lewis-Tuffin L, Patel T. Targeting Liver Cancer Stem Cells Using Engineered Biological Nanoparticles for the Treatment of Hepatocellular Cancer. Hepatol Commun 2020;4:298-313. [PMID: 32025612 DOI: 10.1002/hep4.1462] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
102 Wang H, Yang G, Yu Y, Gu P. MicroRNA-490-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells via targeting TMOD3. Oncol Lett 2020;20:95. [PMID: 32831914 DOI: 10.3892/ol.2020.11956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Xu JH, Chang WH, Fu HW, Yuan T, Chen P. The mRNA, miRNA and lncRNA networks in hepatocellular carcinoma: An integrative transcriptomic analysis from Gene Expression Omnibus. Mol Med Rep 2018;17:6472-82. [PMID: 29512731 DOI: 10.3892/mmr.2018.8694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
104 Wang M, Ye Q, Mao D, Li H. Research Progress in Liver-Regenerating Microenvironment and DNA Methylation in Hepatocellular Carcinoma: The Role of Traditional Chinese Medicine. Med Sci Monit 2020;26:e920310. [PMID: 32144233 DOI: 10.12659/MSM.920310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
105 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
106 Zheng Y, Zhang W, Xu L, Zhou H, Yuan M, Xu H. Recent Progress in Understanding the Action of Natural Compounds at Novel Therapeutic Drug Targets for the Treatment of Liver Cancer. Front Oncol 2021;11:795548. [PMID: 35155196 DOI: 10.3389/fonc.2021.795548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
107 Chen L, Cai BB, Zhou CJ, Hou XQ, Hu SP, Fang G, Chen WC, Li LH, Yang WJ. A sample model established by S-index predicting overall survival after curative resection of primary hepatocellular carcinoma. Cancer Manag Res 2019;11:693-703. [PMID: 30679923 DOI: 10.2147/CMAR.S193593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Yang B, Wang S, Xie H, Wang C, Gao X, Rong Y, Liu Z, Lu Y. KIF18B promotes hepatocellular carcinoma progression through activating Wnt/β-catenin-signaling pathway. J Cell Physiol 2020;235:6507-14. [PMID: 32052444 DOI: 10.1002/jcp.29444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
109 Zhang Q, Xiao Z, Sun S, Wang K, Qian J, Cui Z, Tao T, Zhou J. Integrated Proteomics and Bioinformatics to Identify Potential Prognostic Biomarkers in Hepatocellular Carcinoma. Cancer Manag Res 2021;13:2307-17. [PMID: 33732023 DOI: 10.2147/CMAR.S291811] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Guo J, Wang S, Han Y, Jia Z, Wang R. Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. Oncol Lett 2021;22:554. [PMID: 34084221 DOI: 10.3892/ol.2021.12815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
111 Lallement M, Maulat C, Suc B, Péré G, Lozano S, Bérard E, Muscari F. Short-term autonomy and survival after hepatectomy in the elderly. J Visc Surg 2020;157:378-86. [PMID: 31980381 DOI: 10.1016/j.jviscsurg.2020.01.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Liu DX, Li PP, Guo JP, Li LL, Guo B, Jiao HB, Wu JH, Chen JM. Exosomes derived from HBV-associated liver cancer promote chemoresistance by upregulating chaperone-mediated autophagy. Oncol Lett 2019;17:323-31. [PMID: 30655770 DOI: 10.3892/ol.2018.9584] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
113 Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol 2020;49:1562-71. [PMID: 32725117 DOI: 10.1093/ije/dyaa089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
114 Dirchwolf M, Marciano S, Ruf AE, Singal AG, D'Ercole V, Coisson P, Zerega A, Orozco F, Palazzo A, Fassio E, Arufe D, Anders M, D'Amico C, Gaite L, Thompson M, Perez D, Haddad L, Demirdjian E, Zunino M, Gadano A, Murga MD, Bermudez C, Tomatis J, Grigera N, Antinucci F, Baravalle M, Gazari MMR, Ferreiro M, Barbero M, Curia A, Demonte M, Gualano G. Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice. Ann Hepatol 2021;25:100344. [PMID: 33819695 DOI: 10.1016/j.aohep.2021.100344] [Reference Citation Analysis]
115 Dong Y, Wang Q, Sun J, Liu H, Wang H. Long non-coding RNA TPTEP1 exerts inhibitory effects on hepatocellular carcinoma by impairing microRNA-454-3p-mediated DLG5 downregulation. Dig Liver Dis 2021:S1590-8658(21)00199-7. [PMID: 34238665 DOI: 10.1016/j.dld.2021.04.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Zhang G, Shen S, Yu Y, Yue X, Hu W, Li S. Kinesin family member 2C aggravates the progression of hepatocellular carcinoma and interacts with competing endogenous RNA. J Cell Biochem 2020;121:4419-30. [DOI: 10.1002/jcb.29665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
117 Kalathil SG, Thanavala Y. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells 2021;10:1332. [PMID: 34071188 DOI: 10.3390/cells10061332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Qian Q, Wu C, Chen J, Wang W. Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines. Biomed Res Int. 2020;2020:8910183. [PMID: 32724815 DOI: 10.1155/2020/8910183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Wang H, Xu F, Yang F, Lv L, Jiang Y. Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma. Sci Rep 2021;11:14611. [PMID: 34272452 DOI: 10.1038/s41598-021-93998-9] [Reference Citation Analysis]
120 Huang Y, Wallace MC, Adams LA, MacQuillan G, Garas G, Ferguson J, Samuelson S, Tibballs J, Jeffrey GP. Rate of Nonsurveillance and Advanced Hepatocellular Carcinoma at Diagnosis in Chronic Liver Disease. J Clin Gastroenterol 2018;52:551-6. [PMID: 28858944 DOI: 10.1097/MCG.0000000000000916] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
121 Liu Z, Suo C, Mao X, Jiang Y, Jin L, Zhang T, Chen X. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. Cancer 2020;126:2267-78. [PMID: 32201944 DOI: 10.1002/cncr.32789] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
122 Bento de Sousa JH, Calil IL, Tustumi F, da Cunha Khalil D, Felga GEG, de Arruda Pecora RA, de Almeida MD. Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Gastroenterol Hepatol. 2021;6:11. [PMID: 33409405 DOI: 10.21037/tgh.2020.01.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
123 Wang L, Wang X, Wang X. The effectiveness of enteral nutrition for patients with primary liver cancer: A randomized controlled study protocol. Medicine (Baltimore) 2021;100:e23973. [PMID: 33545982 DOI: 10.1097/MD.0000000000023973] [Reference Citation Analysis]
124 Qi X, Zhao Y, Li H, Guo X, Han G. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget 2016;7:34703-51. [PMID: 27167195 DOI: 10.18632/oncotarget.9157] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
125 Song W, Wenhui Z, Ruiqiang Y, Hu X, Shi T, Wang M, Zhang H. Long noncoding RNA PP7080 promotes hepatocellular carcinoma development by sponging mir-601 and targeting SIRT1. Bioengineered 2021;12:1599-610. [PMID: 33955831 DOI: 10.1080/21655979.2021.1920323] [Reference Citation Analysis]
126 Bi J, Guo Y, Li Q, Liu L, Bao S, Xu P. Role of long intergenic non-protein coding RNA 01857 in hepatocellular carcinoma malignancy via the regulation of the microRNA-197-3p/anterior GRadient 2 axis. PLoS One 2021;16:e0258312. [PMID: 34793477 DOI: 10.1371/journal.pone.0258312] [Reference Citation Analysis]
127 Debes JD, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E, Prieto JE, Tapias M, Idrovo V, Davalos MB, Cairo F. Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver Int. 2018;38:136-143. [PMID: 28640517 DOI: 10.1111/liv.13502] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
128 Manterola C, Grande L, Otzen T, Duque G. Surgical treatment results of hepatocellular carcinoma in non-cirrhotic liver in southern Chile: case series with follow-up. ANZ J Surg 2020;90:92-6. [PMID: 31566295 DOI: 10.1111/ans.15455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, Sirignano C, Abbruzzi F, Barbato F, Landriscina M. Therapeutic Strategies in HCC: Radiation Modalities. Biomed Res Int. 2016;2016:1295329. [PMID: 27563661 DOI: 10.1155/2016/1295329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
130 Zhang Y, Wang H, Li C, Gao L, Zheng Y, Chang W, Lu C, Zhao X. CircSMYD4 regulates proliferation, migration and apoptosis of hepatocellular carcinoma cells by sponging miR-584-5p. Cancer Cell Int 2020;20:556. [PMID: 33292243 DOI: 10.1186/s12935-020-01648-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Cazzetta V, Franzese S, Carenza C, Della Bella S, Mikulak J, Mavilio D. Natural Killer-Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy. Cancers (Basel) 2021;13:2184. [PMID: 34062821 DOI: 10.3390/cancers13092184] [Reference Citation Analysis]
132 Zhang GP, Yue X, Li SQ. Cathepsin C Interacts with TNF-α/p38 MAPK Signaling Pathway to Promote Proliferation and Metastasis in Hepatocellular Carcinoma. Cancer Res Treat 2020;52:10-23. [PMID: 31048666 DOI: 10.4143/crt.2019.145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
133 Cai L, Li H, Guo J, Zhao W, Duan Y, Hou X, Cheng L, Du H, Shao X, Diao Z, Li C. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study. Clin Res Hepatol Gastroenterol 2021;45:101535. [PMID: 33121882 DOI: 10.1016/j.clinre.2020.09.002] [Reference Citation Analysis]
134 Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Acad Radiol 2018;25:423-9. [PMID: 29198946 DOI: 10.1016/j.acra.2017.10.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
135 Jiang YJ, Zhong JH, Zhou ZH, Qiu MQ, Zhou XG, Liu YC, Huo RR, Liang XM, Chen Z, Lin QL, Yu XY, Yu HP. Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma. Cancer Med. 2019;8:2545-2552. [PMID: 30883040 DOI: 10.1002/cam4.2068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
136 Zhou Y, Chai H, Guo L, Dai Z, Lai J, Duan J, Liu Y, Ding Q. Knockdown of CENPW Inhibits Hepatocellular Carcinoma Progression by Inactivating E2F Signaling. Technol Cancer Res Treat 2021;20:15330338211007253. [PMID: 33973496 DOI: 10.1177/15330338211007253] [Reference Citation Analysis]
137 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
138 El Dika I, Khalil DN, Abou-Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer 2019;125:3312-9. [PMID: 31290997 DOI: 10.1002/cncr.32076] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
139 Ji P, Li Z, Dong J, Yi H. SO2 derivatives and As co-exposure promote liver cancer metastasis through integrin αvβ3 activation. Ecotoxicol Environ Saf 2019;181:572-8. [PMID: 31252212 DOI: 10.1016/j.ecoenv.2019.06.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
140 Cheng D, Deng J, Zhang B, He X, Meng Z, Li G, Ye H, Zheng S, Wei L, Deng X, Chen R, Zhou J. LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 2018;36:159-170. [PMID: 30195653 DOI: 10.1016/j.ebiom.2018.08.055] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
141 Zhang C, Yao R, Chen J, Zou Q, Zeng L. S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: A STROBE study. Medicine (Baltimore) 2021;100:e24135. [PMID: 33546025 DOI: 10.1097/MD.0000000000024135] [Reference Citation Analysis]
142 Han L, Wang Y, Sun S. Curcumin inhibits proliferation of hepatocellular carcinoma cells through down regulation of DJ-1. Cancer Biomark 2020;29:1-8. [PMID: 32417759 DOI: 10.3233/CBM-190427] [Reference Citation Analysis]
143 Lian JY, Tuo BG. Role of TGFβ signaling pathway in biological behavior of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2015; 23(24): 3874-3881 [DOI: 10.11569/wcjd.v23.i24.3874] [Reference Citation Analysis]
144 Jin H, Pang Q, Fang M, Wang Y, Man Z, Tan Y, Liu H. Syt-7 overexpression predicts poor prognosis and promotes cell proliferation in hepatocellular carcinoma. Future Oncol 2020;16:2809-19. [PMID: 33052751 DOI: 10.2217/fon-2020-0262] [Reference Citation Analysis]
145 Iwamoto H, Nomiyama M, Niizeki T, Shimose S, Shirono T, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Kuromatsu R, Ogo E, Abe T, Tanaka M, Koga H, Torimura T. Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. Oncology 2019;96:192-9. [PMID: 30650415 DOI: 10.1159/000495568] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
146 Zhang H, Qin L, Li C, Jiang J, Sun L, Zhao X, Li N. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy combined with ganciclovir induces hepatoma cell apoptosis. Exp Ther Med 2019;17:1649-55. [PMID: 30783433 DOI: 10.3892/etm.2019.7147] [Reference Citation Analysis]
147 Wang S, Xiong Z, Liu Y, Leng Y, Deng H, Shen D, Meng X, Liu T. Efficacy and safety of acupuncture and moxibustion combined with the external application of traditional Chinese medicine in the treatment of primary liver cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27659. [PMID: 34713860 DOI: 10.1097/MD.0000000000027659] [Reference Citation Analysis]
148 Fontes A, Alemany-Pagès M, Oliveira PJ, Ramalho-Santos J, Zischka H, Azul AM. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Int J Mol Sci 2019;20:E3987. [PMID: 31426291 DOI: 10.3390/ijms20163987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
149 Wu Q, Chen JX, Chen Y, Cai LL, Wang XZ, Guo WH, Zheng JF. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation. Cell Death Dis 2018;9:232. [PMID: 29445190 DOI: 10.1038/s41419-018-0267-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
150 Zuo WH, Zeng P, Chen X, Lu YJ, Li A, Wu JB. Promotive effects of bone morphogenetic protein 2 on angiogenesis in hepatocarcinoma via multiple signal pathways. Sci Rep. 2016;6:37499. [PMID: 27886213 DOI: 10.1038/srep37499] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
151 Zhang Q, Wang Y, Zhang J, Zhang W, Gong J, Ma R. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study. Technol Cancer Res Treat 2021;20:15330338211060180. [PMID: 34855560 DOI: 10.1177/15330338211060180] [Reference Citation Analysis]
152 Zhang B, Wang HY, Wang DX, Zeng Q, Fan Z, Xi JF, Nan X, He LJ, Zhou JN, Pei XT, Yue W. A new protocol for long-term culture of a specific subpopulation of liver cancer stem cells enriched by cell surface markers. FEBS Open Bio 2020;10:1737-47. [PMID: 32662250 DOI: 10.1002/2211-5463.12932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Mikulak J, Bruni E, Oriolo F, Di Vito C, Mavilio D. Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology. Front Immunol. 2019;10:946. [PMID: 31114585 DOI: 10.3389/fimmu.2019.00946] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
154 Lan H, Lin G, Zhong W. A meta-analysis of the added value of diffusion weighted imaging in combination with contrast-enhanced magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma lesser or equal to 2 cm. Oncol Lett 2020;20:2739-48. [PMID: 32782590 DOI: 10.3892/ol.2020.11805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
155 Martínez-mier G, Esquivel-torres S, Casanova-sánchez I, Escobar-ríos A, Troche-gutiérrez J, Yoldi-aguirre C. Carcinoma hepatocelular en hígado no cirrótico: características clínicas y resultados en Veracruz, México. Revista de Gastroenterología de México 2021;86:4-12. [DOI: 10.1016/j.rgmx.2019.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Chen S, Wu J, Li M, Sun Q, Gong Z, Letcher RJ, Liu C. A high-throughput screening assay for identification of chemicals with liver tumor promoting potential using a transgenic zebrafish line. Chemosphere 2022;297:134169. [PMID: 35245594 DOI: 10.1016/j.chemosphere.2022.134169] [Reference Citation Analysis]
157 Soydal C, Araz M, Nak D, Akkus P, Baltacioğlu MH, Bilgic S, Kucuk NO. Analysis of prognostic factors in patients receiving transarterial radioembolization for unresectable hepatocellular carcinoma. Nucl Med Commun 2020;41:73-7. [PMID: 31800509 DOI: 10.1097/MNM.0000000000001122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
158 Ge S, Huang H, Huang W, Ji R, Chen J, Wu S, Wang L, Huang T, Sheng Y, Yan H, Lu C, Ma L. PSME4 Activates mTOR Signaling and Promotes the Malignant Progression of Hepatocellular Carcinoma. IJGM 2022;Volume 15:885-95. [DOI: 10.2147/ijgm.s344360] [Reference Citation Analysis]
159 Lin Z, Li S, Guo P, Wang L, Zheng L, Yan Z, Chen X, Cheng Z, Yan H, Zheng C, Zhao C. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways. Life Sci 2019;218:197-204. [PMID: 30582951 DOI: 10.1016/j.lfs.2018.12.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
160 Meira Júnior JDD, Fonseca GM, Carvalho Neto FND, Jeismann VB, Kruger JAP, Silva JPM, Coelho FF, Herman P. Platelet-albumin (PAL) score as a predictor of perioperative outcomes and survival in patients with hepatocellular carcinoma undergoing liver resection in a Western center. Surgical Oncology 2022. [DOI: 10.1016/j.suronc.2022.101752] [Reference Citation Analysis]
161 Ding Y, Sun Z, Zhang S, Chen Y, Zhou B, Li G, Sun Q, Zhou D, Ge Y, Yan S, Wang W. Down-regulation of Long Non-coding RNA LINC01554 in Hepatocellular Cancer and its Clinical Significance. J Cancer 2020;11:3369-74. [PMID: 32231743 DOI: 10.7150/jca.40512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
162 Li T, Lv M, Chen X, Yu Y, Zang G, Tang Z. Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA. Drug Des Devel Ther 2019;13:1289-300. [PMID: 31118568 DOI: 10.2147/DDDT.S200610] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
163 Zhang Y, Lan X, Wang Y, Liu C, Cui T. CRNDE mediates the viability and epithelial-mesenchymal transition of renal cell carcinoma via miR-136-5p. J Recept Signal Transduct Res 2021;41:234-44. [PMID: 32808846 DOI: 10.1080/10799893.2020.1805629] [Reference Citation Analysis]
164 Sun J, Yu X, Wang C, Yu C, Li Z, Nie W, Xu X, Miao X, Jin X. RIP-1/c-FLIPL Induce Hepatic Cancer Cell Apoptosis Through Regulating Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). Med Sci Monit 2017;23:1190-9. [PMID: 28270653 DOI: 10.12659/msm.899727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
165 Giannitrapani L, Zerbo M, Amodeo S, Pipitone E, Galia M, Li Cavoli TV, Minissale MG, Licata A, Schiavone C, Brancatelli G, Montalto G, Soresi M. The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center. Biomed Res Int 2020;2020:5309307. [PMID: 32185209 DOI: 10.1155/2020/5309307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171. [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014] [Cited by in Crossref: 615] [Cited by in F6Publishing: 559] [Article Influence: 153.8] [Reference Citation Analysis]
167 Chao X, Miao F, Feng X, Shi H, Wang Y, Wu J, Zhao L, Zhang W, Jiang C. ADCY2 rs10059539 C>T polymorphism confers a decreased risk of hepatocellular carcinoma in Chinese Han women. Eur J Cancer Prev 2021;30:351-6. [PMID: 34010241 DOI: 10.1097/CEJ.0000000000000638] [Reference Citation Analysis]
168 Chin KM, Koh YX, Syn N, Teo JY, Goh BKP, Cheow PC, Chung YFA, Ooi LL, Chan CY, Lee SY. Early Prediction of Post-hepatectomy Liver Failure in Patients Undergoing Major Hepatectomy Using a PHLF Prognostic Nomogram. World J Surg 2020;44:4197-206. [PMID: 32860142 DOI: 10.1007/s00268-020-05713-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
169 Tang J, Huang Z, Xu J, Lv Q, Wang P. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history. Clin Res Hepatol Gastroenterol 2021;:101814. [PMID: 34597848 DOI: 10.1016/j.clinre.2021.101814] [Reference Citation Analysis]
170 Xu W, Zhao D, Huang X, Zhang M, Yin M, Liu L, Wu H, Weng Z, Xu C. The prognostic value and clinical significance of mitophagy-related genes in hepatocellular carcinoma. Front Genet 2022;13:917584. [DOI: 10.3389/fgene.2022.917584] [Reference Citation Analysis]
171 Li Q, Li H, He C, Jing Z, Liu C, Xie J, Ma W, Deng H. The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. Eur J Med Res 2017;22:48. [PMID: 29162156 DOI: 10.1186/s40001-017-0291-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
172 Xie W, Hao J, Zhang K, Fang X, Liu X. Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma with G2/M phase arrest and apoptosis promotion. Biochem Biophys Res Commun 2018;503:2758-63. [PMID: 30119884 DOI: 10.1016/j.bbrc.2018.08.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
173 Dahiya M, Dureja H. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. J Chemother 2021;:1-16. [PMID: 34291704 DOI: 10.1080/1120009X.2021.1955202] [Reference Citation Analysis]
174 Gu JX, Zhang X, Miao RC, Xiang XH, Fu YN, Zhang JY, Liu C, Qu K. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma. World J Gastroenterol 2019; 25(2): 220-232 [PMID: 30670911 DOI: 10.3748/wjg.v25.i2.220] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 68] [Article Influence: 22.0] [Reference Citation Analysis]
175 Li Y, Liu M, Cui J, Yang K, Zhao L, Gong M, Wang Y, He Y, He T, Bi Y. Hepa1-6-FLuc cell line with the stable expression of firefly luciferase retains its primary properties with promising bioluminescence imaging ability. Oncol Lett 2018;15:6203-10. [PMID: 29616102 DOI: 10.3892/ol.2018.8132] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
176 Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, Shivakumar P. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front Oncol 2020;10:627701. [PMID: 33718121 DOI: 10.3389/fonc.2020.627701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
177 Chen J, Yang J, Xu Q, Wang Z, Wu J, Pan L, Huang K, Wang C. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20202063. [PMID: 33605411 DOI: 10.1042/BSR20202063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Liu Y, Liu R, Wang P, Li S, Shen H. Percutaneous implantation of 125iodine seeds for treatment of portal vein tumor thrombosis in hepatocellular carcinoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0657-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
179 Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, Chen Z, Meng Z. Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma. Biosci Rep 2020;40:BSR20194240. [PMID: 32579175 DOI: 10.1042/BSR20194240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Wen Z, Lian L, Ding H, Hu Y, Xiao Z, Xiong K, Yang Q. LncRNA ANCR promotes hepatocellular carcinoma metastasis through upregulating HNRNPA1 expression. RNA Biol 2020;17:381-94. [PMID: 31868085 DOI: 10.1080/15476286.2019.1708547] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
181 Wang J, Han K, Zhang C, Chen X, Li Y, Zhu L, Luo T. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients. Biosci Rep 2021;41:BSR20210583. [PMID: 33988674 DOI: 10.1042/BSR20210583] [Reference Citation Analysis]
182 Schizas D, Mastoraki A, Routsi E, Papapanou M, Tsapralis D, Vassiliu P, Toutouzas K, Felekouras E. Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int 2020;19:515-23. [PMID: 32753331 DOI: 10.1016/j.hbpd.2020.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
183 Serbanescu-Kele Apor de Zalán CMC, Ruiter SJS, van den Berg AP, Pennings JP, de Jong KP. Outcomes after primary and repeat thermal ablation of hepatocellular carcinoma with or without liver transplantation. Eur Radiol 2022. [PMID: 35133486 DOI: 10.1007/s00330-021-08515-3] [Reference Citation Analysis]
184 Xu D, Wang Y, Wu J, Zhang Z, Chen J, Xie M, Tang R, Cheng C, Chen L, Lin S, Luo X, Zheng J. MTIF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo: Molecular mechanisms and therapeutic significance. Pharmacol Res 2021;163:105265. [PMID: 33129983 DOI: 10.1016/j.phrs.2020.105265] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
185 Wang JR, Li TZ, Wang C, Li SM, Luo YH, Piao XJ, Feng YC, Zhang Y, Xu WT, Zhang Y, Zhang T, Wang SN, Xue H, Wang HX, Cao LK, Jin CH. Liquiritin inhibits proliferation and induces apoptosis in HepG2 hepatocellular carcinoma cells via the ROS-mediated MAPK/AKT/NF-κB signaling pathway. Naunyn Schmiedebergs Arch Pharmacol 2020;393:1987-99. [PMID: 31956937 DOI: 10.1007/s00210-019-01763-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
186 Tao NN, Zhou HZ, Tang H, Cai XF, Zhang WL, Ren JH, Zhou L, Chen X, Chen K, Li WY, Liu B, Yang QX, Cheng ST, Huang LX, Huang AL, Chen J. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway. Oncotarget 2016;7:50117-30. [PMID: 27367026 DOI: 10.18632/oncotarget.10319] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
187 Famularo S, Giani A, Di Sandro S, Sandini M, Giacomoni A, Pinotti E, Lauterio A, Gianotti L, De Carlis L, Romano F. Does the Pringle maneuver affect survival and recurrence following surgical resection for hepatocellular carcinoma? A western series of 441 patients. J Surg Oncol 2018;117:198-206. [DOI: 10.1002/jso.24819] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
188 Kang K, Wang X, Meng C, He L, Sang X, Zheng Y, Xu H. The application of single-cell sequencing technology in the diagnosis and treatment of hepatocellular carcinoma. Ann Transl Med 2019;7:790. [PMID: 32042806 DOI: 10.21037/atm.2019.11.116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
189 Zhang X, Zhang X, Li X, Bao H, Li G, Li N, Li H, Dou J. Connection Between CDC20 Expression and Hepatocellular Carcinoma Prognosis. Med Sci Monit 2021;27:e926760. [PMID: 33788826 DOI: 10.12659/MSM.926760] [Reference Citation Analysis]
190 Afaloniati H, Angelopoulou K, Giakoustidis A, Hardas A, Pseftogas A, Makedou K, Gargavanis A, Goulopoulos T, Iliadis S, Papadopoulos V, Papalois A, Mosialos G, Poutahidis T, Giakoustidis D. HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice. Onco Targets Ther 2020;13:5575-88. [PMID: 32606772 DOI: 10.2147/OTT.S250233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
191 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
192 Tang H, Peng S, Dong Y, Yang X, Yang P, Yang L, Yang B, Bao G. MARCH5 overexpression contributes to tumor growth and metastasis and associates with poor survival in breast cancer. Cancer Manag Res 2019;11:201-15. [PMID: 30636894 DOI: 10.2147/CMAR.S190694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
193 Zhao NH, Qian Y, Wu CS, Wang JW, Fang Y, Fan XP, Gao S, Fan YC, Wang K. Diagnostic value of NKG2D promoter methylation in hepatitis B virus-associated hepatocellular carcinoma. Biomark Med 2019;13:1093-105. [PMID: 31411040 DOI: 10.2217/bmm-2019-0102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
194 Ma X, Gu J, Wang K, Zhang X, Bai J, Zhang J, Liu C, Qiu Q, Qu K. Identification of a molecular subtyping system associated with the prognosis of Asian hepatocellular carcinoma patients receiving liver resection. Sci Rep 2019;9:7073. [PMID: 31068611 DOI: 10.1038/s41598-019-43548-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
195 Kong XQ, Dong YP, Wu JX, He JY, Le YY, Du KX, Peng QQ, Li JL. High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. Radiat Oncol 2017;12:92. [PMID: 28569169 DOI: 10.1186/s13014-017-0831-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
196 Kim TS, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. J Gastroenterol Hepatol 2019;34:2028-35. [PMID: 31157456 DOI: 10.1111/jgh.14750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
197 Zhang T, Zhang L, Han D, Tursun K, Lu X. Circular RNA hsa_Circ_101141 as a Competing Endogenous RNA Facilitates Tumorigenesis of Hepatocellular Carcinoma by Regulating miR-1297/ROCK1 Pathway. Cell Transplant 2020;29:963689720948016. [PMID: 32787581 DOI: 10.1177/0963689720948016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
198 Tom G, Philip S, Isaac R, Praseetha P, Jiji S, Asha V. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma. Life Sciences 2018;206:10-21. [DOI: 10.1016/j.lfs.2018.04.046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
199 Zhou Y, Li W, Tseng Y, Zhang J, Liu J. Developing slow-off dickkopf-1 aptamers for early-diagnosis of hepatocellular carcinoma. Talanta. 2019;194:422-429. [PMID: 30609553 DOI: 10.1016/j.talanta.2018.10.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
200 Wu Q, Liu TY, Hu BC, Li X, Wu YT, Sun XT, Jiang XW, Wang S, Qin XC, Ding HW, Zhao QC. CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways. Front Oncol 2021;11:717626. [PMID: 34395292 DOI: 10.3389/fonc.2021.717626] [Reference Citation Analysis]
201 Dong X, Wang F, Liu C, Ling J, Jia X, Shen F, Yang N, Zhu S, Zhong L, Li Q. Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma. Cell Death Discov 2021;7:14. [PMID: 33462196 DOI: 10.1038/s41420-021-00403-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Jreige M, Mitsakis P, Van Der Gucht A, Pomoni A, Silva-Monteiro M, Gnesin S, Boubaker A, Nicod-Lalonde M, Duran R, Prior JO, Denys A, Schaefer N. 18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2017;44:1215-1222. [PMID: 28233086 DOI: 10.1007/s00259-017-3653-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
203 Gong S, Xu D, Zou F, Peng R. (−)-Curine induces cell cycle arrest and cell death in hepatocellular carcinoma cells in a p53-independent way. Biomedicine & Pharmacotherapy 2017;89:894-901. [DOI: 10.1016/j.biopha.2017.01.148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
204 Tao M, Zheng M, Xu Y, Ma S, Zhang W, Ju S. CircRNAs and their regulatory roles in cancers. Mol Med 2021;27:94. [PMID: 34445958 DOI: 10.1186/s10020-021-00359-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Gu Y, Li J, Guo D, Chen B, Liu P, Xiao Y, Yang K, Liu Z, Liu Q. Identification of 13 Key Genes Correlated With Progression and Prognosis in Hepatocellular Carcinoma by Weighted Gene Co-expression Network Analysis. Front Genet 2020;11:153. [PMID: 32180800 DOI: 10.3389/fgene.2020.00153] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
206 Zhong XZ, Deng Y, Chen G, Yang H. Investigation of the clinical significance and molecular mechanism of miR-21-5p in hepatocellular carcinoma: A systematic review based on 24 studies and bioinformatics investigation. Oncol Lett 2019;17:230-46. [PMID: 30655760 DOI: 10.3892/ol.2018.9627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
207 Wu D, Zhang R, Zhan L. Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile. Clin Res Hepatol Gastroenterol 2021;46:101812. [PMID: 34597849 DOI: 10.1016/j.clinre.2021.101812] [Reference Citation Analysis]
208 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
209 Wang H, Wang B, Wang T, Fan R. A genetic variant in the promoter region of miR-877 is associated with an increased risk of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2020;44:692-8. [PMID: 32113822 DOI: 10.1016/j.clinre.2020.01.006] [Reference Citation Analysis]
210 Xue Y, Jia X, Li L, Dong X, Ling J, Yuan J, Li Q. DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway. Biochem Biophys Res Commun 2018;503:2885-91. [PMID: 30119889 DOI: 10.1016/j.bbrc.2018.08.063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
211 Wang J, Hou Y, Sun Y, Fang F, Luo C, Wang X. A chemiluminescence aptasensor for sensitive detection of alpha-fetoprotein based on hemin@ZIF-67. Anal Bioanal Chem 2022. [PMID: 35508645 DOI: 10.1007/s00216-022-04099-z] [Reference Citation Analysis]
212 Liebig M, Dannenberger D, Vollmar B, Abshagen K. n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model. Ther Adv Chronic Dis 2019;10:2040622319872118. [PMID: 31523414 DOI: 10.1177/2040622319872118] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]